PH

Peter Hecht

Director at Kallyope

Peter is the CEO of Cyclerion Therapeutics. Prior to joining Cyclerion in 2019, Peter was co-founder and CEO of Ironwood Pharmaceuticals from 1998 to 2019. Under his leadership, Ironwood grew into a fully integrated research, development and commercial organization with more than 700 employees. During his tenure the company discovered, developed and commercialized LINZESS® (linaclotide) globally for irritable bowel syndrome with constipation and chronic constipation. In 2019, Peter led the tax-free separation of Ironwood's non-gastrointestinal (GI) assets and R&D team into Cyclerion, enabling Ironwood to be a profitable GI therapeutics-focused leader. After completion of the spin-off, Hecht joined Cyclerion as its first CEO. He holds a Ph.D. in molecular biology from the University of California at Berkeley and was a post-doctoral research fellow at the Whitehead Institute.

Timeline

  • Director

    Current role